Cargando…

Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania

An outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2, initially in December 2019 at Wuhan, China, subsequently spread around the world. We describe a case series of COVID-19 patients treated at our academic medical center with focus on cytokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Suresh, Krithika, Figart, Michael, Formeck, Samantha, Mehmood, Talha, Abdel Salam, Mahmoud, Bassilly, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193653/
https://www.ncbi.nlm.nih.gov/pubmed/34105382
http://dx.doi.org/10.1177/23247096211019557
_version_ 1783706270129192960
author Suresh, Krithika
Figart, Michael
Formeck, Samantha
Mehmood, Talha
Abdel Salam, Mahmoud
Bassilly, David
author_facet Suresh, Krithika
Figart, Michael
Formeck, Samantha
Mehmood, Talha
Abdel Salam, Mahmoud
Bassilly, David
author_sort Suresh, Krithika
collection PubMed
description An outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2, initially in December 2019 at Wuhan, China, subsequently spread around the world. We describe a case series of COVID-19 patients treated at our academic medical center with focus on cytokine storm and potential therapeutic role of tocilizumab. A 59-year-old female admitted for shortness of breath (SOB), productive cough, fever, and nausea in the setting of COVID-19 pneumonia. Oxygen saturation was 81% necessitating supplemental oxygen. She was transferred to intensive care unit (ICU) for worsening hypoxia; intubated and received tocilizumab following which her oxygen requirements improved. A 52-year-old female admitted from an outside hospital with SOB, intubated for worsening hypoxia, in the setting of COVID-19 pneumonia. She received tocilizumab 400 mg intravenous for 2 doses on ICU admission, with clinical improvement. A 56-year-old female hospitalized with worsening SOB, fever, and cough for 8 days saturating 88% on room air in the setting of COVID-19 pneumonia. Worsening hypoxia necessitated high flow nasal cannula. She was transferred to the ICU where she received 2 doses of tocilizumab 400 mg intravenous. She did not require intubation and was transitioned to nasal cannula. A hyperinflammatory syndrome may cause a life-threatening acute respiratory distress syndrome in patients with COVID-19 pneumonia. Tocilizumab is the first marketed interleukin-6 blocking antibody, and through targeting interleukin-6 receptors likely has a role in treating cytokine storm. We noted clinical improvement of patients treated with tocilizumab.
format Online
Article
Text
id pubmed-8193653
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-81936532021-06-24 Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania Suresh, Krithika Figart, Michael Formeck, Samantha Mehmood, Talha Abdel Salam, Mahmoud Bassilly, David J Investig Med High Impact Case Rep Case Report An outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2, initially in December 2019 at Wuhan, China, subsequently spread around the world. We describe a case series of COVID-19 patients treated at our academic medical center with focus on cytokine storm and potential therapeutic role of tocilizumab. A 59-year-old female admitted for shortness of breath (SOB), productive cough, fever, and nausea in the setting of COVID-19 pneumonia. Oxygen saturation was 81% necessitating supplemental oxygen. She was transferred to intensive care unit (ICU) for worsening hypoxia; intubated and received tocilizumab following which her oxygen requirements improved. A 52-year-old female admitted from an outside hospital with SOB, intubated for worsening hypoxia, in the setting of COVID-19 pneumonia. She received tocilizumab 400 mg intravenous for 2 doses on ICU admission, with clinical improvement. A 56-year-old female hospitalized with worsening SOB, fever, and cough for 8 days saturating 88% on room air in the setting of COVID-19 pneumonia. Worsening hypoxia necessitated high flow nasal cannula. She was transferred to the ICU where she received 2 doses of tocilizumab 400 mg intravenous. She did not require intubation and was transitioned to nasal cannula. A hyperinflammatory syndrome may cause a life-threatening acute respiratory distress syndrome in patients with COVID-19 pneumonia. Tocilizumab is the first marketed interleukin-6 blocking antibody, and through targeting interleukin-6 receptors likely has a role in treating cytokine storm. We noted clinical improvement of patients treated with tocilizumab. SAGE Publications 2021-06-09 /pmc/articles/PMC8193653/ /pubmed/34105382 http://dx.doi.org/10.1177/23247096211019557 Text en © 2021 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Suresh, Krithika
Figart, Michael
Formeck, Samantha
Mehmood, Talha
Abdel Salam, Mahmoud
Bassilly, David
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania
title Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania
title_full Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania
title_fullStr Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania
title_full_unstemmed Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania
title_short Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania
title_sort tocilizumab for the treatment of covid-19-induced cytokine storm and acute respiratory distress syndrome: a case series from a rural level 1 trauma center in western pennsylvania
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193653/
https://www.ncbi.nlm.nih.gov/pubmed/34105382
http://dx.doi.org/10.1177/23247096211019557
work_keys_str_mv AT sureshkrithika tocilizumabforthetreatmentofcovid19inducedcytokinestormandacuterespiratorydistresssyndromeacaseseriesfromarurallevel1traumacenterinwesternpennsylvania
AT figartmichael tocilizumabforthetreatmentofcovid19inducedcytokinestormandacuterespiratorydistresssyndromeacaseseriesfromarurallevel1traumacenterinwesternpennsylvania
AT formecksamantha tocilizumabforthetreatmentofcovid19inducedcytokinestormandacuterespiratorydistresssyndromeacaseseriesfromarurallevel1traumacenterinwesternpennsylvania
AT mehmoodtalha tocilizumabforthetreatmentofcovid19inducedcytokinestormandacuterespiratorydistresssyndromeacaseseriesfromarurallevel1traumacenterinwesternpennsylvania
AT abdelsalammahmoud tocilizumabforthetreatmentofcovid19inducedcytokinestormandacuterespiratorydistresssyndromeacaseseriesfromarurallevel1traumacenterinwesternpennsylvania
AT bassillydavid tocilizumabforthetreatmentofcovid19inducedcytokinestormandacuterespiratorydistresssyndromeacaseseriesfromarurallevel1traumacenterinwesternpennsylvania